Source comparison
MK-677 Help Perimenopause Research: Comparison
MK-677 (ibutamoren) Ghrelin receptor agonist. Stimulates endogenous GH and IGF-1 secretion Bone density, sleep architecture, lean mass preservation Moderate. Phase II and observational trials in postmenopausal women show 3–5% BMD increase and 50–75% sleep impr
This comparison does not assign a generated winner or score.
- MK-677 (ibutamoren)
- Ghrelin receptor agonist. Stimulates endogenous GH and IGF-1 secretion
- Bone density, sleep architecture, lean mass preservation
- Moderate. Phase II and observational trials in postmenopausal women show 3–5% BMD increase and 50–75% sleep improvement
- 4–8 weeks for sleep; 12–24 months for bone density changes
- Promising for GH-dependent symptoms that HRT doesn't address, but not a direct estrogen replacement
- Estrogen HRT
- Estrogen receptor agonist. Replaces circulating estrogen
- Hot flashes, vaginal atrophy, bone loss, cardiovascular protection
- High. Decades of RCTs and meta-analyses establish efficacy and risk profiles
- 2–4 weeks for vasomotor symptoms; 6–12 months for bone effects
- Gold standard for estrogen-dependent symptoms but doesn't address GH axis decline
- Bisphosphonates (alendronate)
- Inhibits osteoclast-mediated bone resorption
- Bone density preservation only
- High. Proven fracture reduction in large RCTs
- 12–24 months for measurable BMD improvement
- Effective for bone but no impact on sleep, metabolism, or lean mass. Purely anti-resorptive
- Selective Estrogen Receptor Modulators (raloxifene)
- Estrogen agonist in bone, antagonist in breast and uterus
- Bone density with reduced breast cancer risk
- High. RCT evidence for fracture reduction and cancer risk
- 12–18 months for bone effects
- Lower efficacy than HRT for vasomotor symptoms; bone benefits without full estrogen exposure
- Exercise + Protein Supplementation
- Mechanical loading stimulates osteoblasts; leucine activates mTOR for muscle protein synthesis
- Bone density, lean mass, insulin sensitivity
- High. Consistent observational and intervention data
- 6–12 months for bone and body composition changes
- Foundational but insufficient alone for severe BMD decline. Synergistic with pharmacological interventions